Cullinan Therapeutics (CGEM) Income from Non-Controlling Interests (2020 - 2024)

Cullinan Therapeutics' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$893000.0 for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests fell 239.97% year-over-year to -$893000.0; the TTM figure through Mar 2026 stood at -$1.9 million (down 197.83% YoY), while the FY2024 annual figure was -$192000.0, up 90.1% from the prior year.
• Income from Non-Controlling Interests for Q1 2026 stood at -$893000.0, up from -$1.1 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $1.4 million in Q3 2024, with the low at -$2.3 million in Q1 2022.
• The 5-year median for Income from Non-Controlling Interests is -$254000.0 (2022), against an average of -$295071.4.
• The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests plunged 475.16% in 2023, then jumped 415.84% in 2025.
• Cullinan Therapeutics' Income from Non-Controlling Interests stood at -$306000.0 in 2022, then slumped by 475.16% to -$1.8 million in 2023, then surged by 182.16% to $1.4 million in 2024, then tumbled by 176.49% to -$1.1 million in 2025, then increased by 19.26% to -$893000.0 in 2026.
• Business Quant data shows CGEM's Income from Non-Controlling Interests at -$893000.0 in Q1 2026, -$1.1 million in Q4 2025, and $102000.0 in Q2 2025.